TickerLeague

EBITDA for Viatris (VTRS)

According to Viatris's latest reported financial statements, the company's current EBITDA (TTM) is -$395.40M USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

TTM (last 4 quarters)

-$395.40M

YoY change

-114.0%

5Y CAGR

N/A

Peak year (2022)

$6.43B

Cumulative EBITDA

$41.75B

EBITDA history chart for Viatris (VTRS) from 2003 to 2025

EBITDA history table for Viatris (VTRS) from 2003 to 2025

Fiscal yearPeriod endedReportedEBITDAYoY
2025-$395.40M-114.0%
2024$2.82B-19.8%
2023$3.52B-45.3%
2022$6.43B+43.7%
2021$4.48B+124.7%
2020$1.99B-25.9%
2019$2.69B-8.8%
2018$2.95B-9.0%
2017$3.24B+54.5%
2016$2.10B-8.2%
2015$2.29B+22.0%
2014$1.87B+18.9%
2013$1.58B-5.0%
2012$1.66B+10.5%
2011$1.50B+35.2%
2010$1.11B+17.3%
2009$946.63M+28.9%
2008$734.50M-174.1%
2007-$991.80M
2005$334.21M-3.8%
2004$347.27M-35.6%
2003$539.12M

EBITDA values are taken from Viatris's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

Analysis

In 2025, Viatris (VTRS) EBITDA totalled -$395.40M – plunged 114.0% year-over-year.

Between 2022 and 2025, Viatris EBITDA plunged 106.1%, falling from $6.43B to -$395.40M.

2022 marks the peak EBITDA at $6.43B, with the historical low of -$991.80M recorded in 2007.

Viatris (VTRS) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.

Viatris EBITDA by Year

Viatris EBITDA 2025: -$395.40M

Viatris EBITDA in 2025 was -$395.40M, plunged 114.0% below 2024.

Viatris EBITDA 2024: $2.82B

Viatris EBITDA in 2024 was $2.82B, declined 19.8% below 2023.

Viatris EBITDA 2023: $3.52B

Viatris EBITDA in 2023 was $3.52B, plunged 45.3% below 2022.

Viatris EBITDA 2022: $6.43B

Viatris EBITDA in 2022 was $6.43B, surged 43.7% from 2021. This figure represents the highest annual value in the available history.

Viatris EBITDA 2021: $4.48B

Viatris EBITDA in 2021 was $4.48B.

See more financial history for Viatris (VTRS).

Sector peers — EBITDA

Companies in the same sector as Viatris, ranked by their latest EBITDA.

CompanyEBITDASector
Novo Nordisk A/S (NVO)$156.73BHealthcare
Johnson & Johnson (JNJ)$41.05BHealthcare
Eli Lilly and Company (LLY)$27.94BHealthcare
Merck & Co., Inc. (MRK)$25.36BHealthcare
UnitedHealth Group Incorporated (UNH)$23.06BHealthcare
AstraZeneca PLC (AZN)$19.83BHealthcare
AbbVie Inc. (ABBV)$17.63BHealthcare
Amgen Inc. (AMGN)$15.84BHealthcare

Frequently asked questions

What is Viatris's EBITDA?

Latest reported EBITDA for Viatris (VTRS) is -$395.40M (period ending December 31, 2025).

How has Viatris EBITDA changed year-over-year?

Viatris (VTRS) EBITDA changed -114.0% year-over-year on the latest annual filing.

When did Viatris EBITDA hit its highest annual value?

Viatris EBITDA reached its highest annual value of $6.43B in 2022.

What was Viatris EBITDA in 2024?

Viatris (VTRS) EBITDA in 2024 was $2.82B.

What was Viatris EBITDA in 2025?

Viatris (VTRS) EBITDA in 2025 was -$395.40M.

Metrics overview

Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.